Positive Results for Jardiance in CV Risk Reduction Study
Boehringer Ingelheim and Lilly announced positive results from the EMPA-REG OUTCOME trial that evaluated cardiovascular (CV) outcomes for Jardiance (empagliflozin) in adults with type 2 diabetes at high risk for CV events.
EMPA-REG OUTCOME was a multicenter, randomized, double-blind, placebo-controlled long-term trial that studied over 7,000 patients for a median duration of 3.1 years. The study aimed to evaluate the effect of Jardiance 10mg or 25mg once daily plus standard of care vs. placebo plus standard of care on CV events in high-risk adults with type 2 diabetes. Standard of care consisted of glucose lowering agents and CV drugs, such as antihypertensive and lipid lowering agents.
The study met its primary endpoint, defined as time to first occurrence of CV death, non-fatal myocardial infarction or non-fatal stroke. The study showed superiority of Jardiance when added to standard of care in CV risk reduction. Jardiance also demonstrated a similar safety profile consistent with earlier studies.
Jardiance, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
For more information call (800) 542-6257 or visit Jardiance.com.